MedTrace Logo

Statin Discontinuation in Advanced Illness

NCT01415934 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 381

Last updated 2018-09-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if there is a difference in survival rate at 60 days after enrollment between patients with advanced life-limiting illness for whom statins are discontinued vs. for patients with advanced life-limiting illness who are maintained on the medication. Secondary outcomes of this study will determine the effects of medication cessation on overall survival, important cardiovascular events, quality of life (QOL), symptoms, performance status, polypharmacy issues, satisfaction with care, and costs.

Conditions

Interventions

OTHER

discontinue statins

patients will be randomized to either continue taking statins or discontinue.

Sponsors & Collaborators

  • National Institute of Nursing Research (NINR)

    collaborator NIH

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Amy Abernethy, MD · Duke University

  • Jean Kutner, MD · University of Colorado, Denver

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-03
Primary Completion
2013-07-15
Completion
2013-07-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01415934 on ClinicalTrials.gov